The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The Changing Face of Prostate Cancer
Open accessAbstract
Prostate cancer remains the most common noncutaneous human malignancy, and the second most lethal tumor among men. However, the natural history of the disease is often prolonged, and the survival benefits of local therapy for men with low-risk tumors may not be realized for a decade or more, as is increasingly well demonstrated in long-term observational cohorts in both the United States and Europe. A significant proportion of men with prostate cancer may be overdiagnosed, in the sense that diagnosis may not improve their lifespan or quality of life. However, the extent to which overdiagnosis represents a true problem relates to the consistency with which diagnosis leads invariably to active treatment. Prostate cancer is diagnosed at progressively earlier stages and with lower risk features; despite these trends, patients are less likely now than a decade ago to undergo a trial of active surveillance. Rates of brachytherapy and hormonal therapy use, in particular, have risen markedly. Important progress has been made in recent years in prostate cancer risk assessment. These advances, in combination with biomarkers in later stages of development, should be expected in the coming years to yield further improvements in clinicians' ability to diagnose prostate cancer early, and guide appropriately selected patients toward increasingly tailored treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Bratell, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011967 · Cited by 1,900
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Häggman, M., Andersson, S.-O., Bratell, S., Spångberg, A., Busch, C., Nordling, S., Garmo, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043739 · Cited by 1,111
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Etzioni, R. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.13.981 · Cited by 949
COOPERBERG, M. R., PASTA, D. J., ELKIN, E. P., LITWIN, M. S., LATINI, D. M., Du CHANE, J., & CARROLL, P. R. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158155.33890.e7 · Cited by 772
Self-citationPilepich, M. V., Winter, K., John, M. J., Mesic, J. B., Sause, W., Rubin, P., Lawton, C., Machtay, M., & Grignon, D. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01579-6 · Cited by 772
Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy
D'Amico, A. V., Chen, M.-H., Roehl, K. A., & Catalona, W. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032975 · Cited by 740
Natural History of Early, Localized Prostate Cancer
Johansson, J.-E. (2004) · JAMA · doi:10.1001/jama.291.22.2713 · Cited by 703
Pilepich, M. V., Caplan, R., Byhardt, R. W., Lawton, C. A., Gallagher, M. J., Mesic, J. B., Hanks, G. E., Coughlin, C. T., Porter, A., Shipley, W. U., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1013 · Cited by 607
Wei, J. T., Dunn, R. L., Sandler, H. M., McLaughlin, P. W., Montie, J. E., Litwin, M. S., NYQUIST, L. V., & Sanda, M. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.557 · Cited by 443
Amling, C. L., Riffenburgh, R. H., Sun, L., Moul, J. W., Lance, R. S., Kusuda, L., Sexton, W. J., Soderdahl, D. W., Donahue, T. F., Foley, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.132 · Cited by 385
Self-citationFreedland, S. J., Aronson, W. J., Kane, C. J., Presti, J. C., Amling, C. L., Elashoff, D., & Terris, M. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.181 · Cited by 384
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Self-citationThe capsure database: a methodology for clinical practice and research in prostate cancer
Lubeck, D. P., Litwin, M. S., Henning, J. M., Stier, D. M., Mazonson, P., Fisk, R., Carroll, P. R., & panel, T. C. R. (1996) · Urology · doi:10.1016/s0090-4295(96)00226-9 · Cited by 268
Self-citationBody mass index and risk of prostate cancer in U.S. health professionals
Giovannucci, E., Rimm, E. B., Liu, Y., Leitzmann, M., Wu, K., Stampfer, M. J., & Willett, W. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg009 · Cited by 258
Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S., Gilliland, F. D., Eley, J. W., Stephenson, R. A., & Hoffman, R. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3750 · Cited by 251
Anthropometry in Relation to Prostate Cancer Risk in the Netherlands Cohort Study
Schuurman, A. G., Goldbohm, R. A., Dorant, E., & van den Brandt, P. A. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010241 · Cited by 208
Harlan, L. C., Potosky, A., Gilliland, F. D., Hoffman, R., Albertsen, P. C., Hamilton, A. S., Eley, J. W., Stanford, J. L., & Stephenson, R. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1864 · Cited by 192
Meng, M. V., Elkin, E. P., Latini, D. M., DuChane, J., & Carroll, P. R. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000154610.81916.81 · Cited by 136
Self-citationD'Amico, A. V., Renshaw, A. A., Cote, K., Hurwitz, M., Beard, C. J., Loffredo, M. J., & Chen, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.164 · Cited by 123
Jung, K., Elgeti, U., Lein, M., Brux, B., Sinha, P. K., Rudolph, B. D., Hauptmann, S., Schnorr, D., & Loening, S. A. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.1.55 · Cited by 97
Grossfeld, G. D., Latini, D. M., Lubeck, D. P., Broering, J. M., Li, Y.-P., Mehta, S. S., & Carroll, P. R. (2002) · Urology · doi:10.1016/s0090-4295(01)01658-2 · Cited by 88
Self-citationDudek, A. Z., Larson, T. A., Mellskog, C. E., Bloss, L. P., & Obasaju, C. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2141 · Cited by 14
Cited by
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2008.11.032 · Cited by 1,227
Thompson, R. H., Boorjian, S. A., Lohse, C. M., Leibovich, B. C., Kwon, E. D., Cheville, J. C., & Blute, M. L. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.09.077 · Cited by 713
Metadata
- Authors
- Cooperberg, M. R., Moul, J. W., & Carroll, P. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-10
- Volume
- 23
- Issue
- 32
- Pages
- 8146-8151
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1999843388
- Cited by
- 318
- References
- 29
- FWCI
- 19.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.